Biophytis Sa · EURONEXT:ALBPS
Biophytis Sa — Shareholder Meeting (April 2021)
16 slides from Biophytis Sa's shareholder meeting presentation, Apr 26, 2021
Slide 1: AGM April 26, 2021
AGM April 26, 2021 April 2021 I Euronext: ALBPS – Nasdaq: BPTS
Slide 2: Forward Looking Statements
Forward Looking Statements All statements pertaining to future financial and/or operating results, future growth in research, clinical development, and potential opportunities for Biophytis SA (the “Company”) and its products, along with other statements about the future expectations, beliefs, goals
Slide 3: Agenda
Agenda Result AGM April 26, 2021 First 1 Call 2 2020 Key achievements 3 Clinical pipeline update Upcoming milestones and 4 outlook 19
Slide 4: AGM Results
AGM Results • Biophytis’ combined AGM was called today behind closed doors, due to the COVID-19 pandemic. • The shareholders taking part in the vote owned collectively 21 736 509 shares, or 19.11% of the share capital, and 19.46% of the voting rights. • The 20% quorum necessary for holding an ordina
Slide 5: Biophytis is a clinical-stage biotechnology company specialized in age-related diseases
Biophytis is a clinical-stage biotechnology company specialized in age-related diseases • Prevent disabilities (muscular, respiratory and vision) and increase health span for patients suffering from age-related diseases. Our mission • Our small molecules are aimed at stimulating biological resilienc
Slide 6: 2020 was a transformational year for Biophytis
2020 was a transformational year for Biophytis with great operational and financial performance Clinical Achievements Financial achievements Launch of the new COVA study – COVID-19 • Successful completion of four • Part 1 first interim analysis achieved (50 patients) with positive private placements
Slide 7: Our clinical pipeline is progressing and expanding since last year
Our clinical pipeline is progressing and expanding since last year Candidate Indication Program Preclinical Phase 1 Phase 2 Phase 3 Covid-19 COVA Sarconeos Sarcopenia SARA (BIO101) DMD MYODA Dry AMD MACA Macuneos (BIO201) Stargardt • Second generation drug candidates, BIO103 and BIO203, are life-cyc
Slide 8: Sarconeos (BIO101) is believed to activate MAS receptor
Sarconeos (BIO101) is believed to activate MAS receptor, a key factor for muscle and respiratory functions • MAS receptor: a key component of the Renin-Angiotensin System (RAS) • Triggers two important downstream signaling-pathways in myocytes: MAS PI3K/AKT/mTOR: Increases protein synthesis, Recepto
Slide 9: Sarconeos (BIO101) for respiratory failure in COVID-19
Sarconeos (BIO101) for respiratory failure in COVID-19 • SARS-CoV-2 uses ACE2 to penetrate the lungs destabilizing RAS system and causing respiratory failures • Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS system 25
Slide 10: The COVA study in COVID-19 is now in clinical phase 3
The COVA study in COVID-19 is now in clinical phase 3 • iDMC recommends the continuation of part 2 recruitment • More than 97 patients enrolled as of March in 28 clinical centers • Second interim analysis (155 patients) expected in Q2 2021 Design End Point Endpoints Patient Population • A Phase 2/3
Slide 11: The SARA-INT Phase 2 sarcopenia trial is nearing completion
The SARA-INT Phase 2 sarcopenia trial is nearing completion • Last patient out in December 2020: 196 participants completed the study over 233 patients initially enrolled with sarcopenia at risk of mobility disability over 22 centers in the US and Belgium • Topline results in sarcopenia expected in
Slide 12: MYODA plans to start Phase 1-2-3 clinical study during H1 2021
MYODA plans to start Phase 1-2-3 clinical study during H1 2021* Design Endpoints Patient Population • Global, multicenter, double-blind, • Part 1 (N=18): Safety, tolerability • Age: ≥12 years old placebo-controlled, seamless, & PK (initial 7 days of dosing of • Non-ambulatory DMD patients Phase 1-2-
Slide 13: Successful US IPO in addition to PIPEs on Euronext totaling €40M
Successful US IPO in addition to PIPEs on Euronext totaling €40M U.S. Initial Public Offering 2020 Euronext Financings In February 2021, the Company closed an The Company successfully closed four private initial public offering on the NASDAQ placement transactions (BPTS) Public offering gross procee
Slide 14: Key programs milestones
Key programs milestones COVA Started in Belgium, Brazil, France and US COVA Completion of patient enrollment (Part 1) in January 2021 COVA Interim analysis of Part 1 (50 patients) in Q1 2021 COVA Approvals to start Part 2 in Q1 2021 COVA Interim analysis for Part 2 (155 patients) expected before end
Slide 15: 2021 Outlook
2021 Outlook The COVA study • Full results (Part 1 and Part 2) are expected in Q2 2021 • Assuming positive data, subject to any COVID-19 related delays, the Company anticipates applying for EUA in the US and conditional market approvals in EU in Q3 2021. • Assuming authorizations for the above appli
Slide 16: Thank you
CONTACTS: Stanislas Veillet – CEO stanislas.veillet@biophytis.com Evelyne NGUYEN – CFO evelyne.nguyen@biophytis.com Thank you Investor relations: investors@biophytis.com Website: www.biophytis.com 32